Jie (Jay) Cheng, MD, PhD

Dr. Jie Cheng earned his medical degree from Shanghai Medical University in Shanghai City, Shanghai, China. He received residency training in internal medicine and received a Ph.D. in biomedical engineering at Case Western Reserve University in Cleveland, Ohio. Dr. Cheng’s fellowship in cardiology was completed at the University of Chicago in Illinois and his fellowship in electrophysiology was completed at the University of California in San Francisco. He is board-certified in electrophysiology and cardiology and specializes in cardiovascular disease and cardiac electrophysiology.

See Publications

Texas Heart Institute Positions

  • Director, Electrophysiology Basic Research
  • Teaching Staff, Cardiovascular Disease Fellowship
  • Teaching Staff, Clinical Cardiac Electrophysiology Fellowship

Interests

  • Cardiology
  • Electrophysiology

Education

  • Medical School:

    Shanghai Jiao Tong University School of Medicine

  • Residency:

    Mount Sinai Medical Center

  • Fellowships:

    University of Chicago

Academic & Clinical Affiliations

  • Baylor St. Luke's Medical Center
  • Memorial Hermann

Honors, Awards and Memberships

Publications

4862227 8EPJLFD3 1 alternatives-to-animal-experimentation 10 date desc Cheng 1864 https://www.texasheart.org/wp-content/plugins/zotpress/
%7B%22status%22%3A%22success%22%2C%22updateneeded%22%3Afalse%2C%22instance%22%3Afalse%2C%22meta%22%3A%7B%22request_last%22%3A0%2C%22request_next%22%3A0%2C%22used_cache%22%3Atrue%7D%2C%22data%22%3A%5B%7B%22key%22%3A%22F7UUFCS7%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222022-11-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZhang%2C%20Y.%2C%20Sun%2C%20C.%2C%20Li%2C%20Y.%20et%20al.%20%282022%29.%20Hormonal%20therapies%20up-regulate%20MANF%20and%20overcome%20female%20susceptibility%20to%20immune%20checkpoint%20inhibitor%20myocarditis.%20%26lt%3Bi%26gt%3BSci%20Transl%20Med%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B14%26lt%3B%5C%2Fi%26gt%3B%2C%20eabo1981.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abo1981%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1126%5C%2Fscitranslmed.abo1981%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Hormonal%20therapies%20up-regulate%20MANF%20and%20overcome%20female%20susceptibility%20to%20immune%20checkpoint%20inhibitor%20myocarditis%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaohua%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcao%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yajuan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juan%22%2C%22lastName%22%3A%22Qin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Kaushik%22%2C%22lastName%22%3A%22Amancherla%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ying%22%2C%22lastName%22%3A%22Jing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qingsong%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ke%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhao%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Youqiong%22%2C%22lastName%22%3A%22Ye%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%20A.%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tina%20K.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergey%20D.%22%2C%22lastName%22%3A%22Egranov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zilong%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrew%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yutao%22%2C%22lastName%22%3A%22Xi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jun%22%2C%22lastName%22%3A%22Yao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mien-Chie%22%2C%22lastName%22%3A%22Hung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22George%20A.%22%2C%22lastName%22%3A%22Calin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bora%22%2C%22lastName%22%3A%22Lim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lorenz%20H.%22%2C%22lastName%22%3A%22Lehmann%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Joe-Elie%22%2C%22lastName%22%3A%22Salem%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Douglas%20B.%22%2C%22lastName%22%3A%22Johnson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Michael%20A.%22%2C%22lastName%22%3A%22Curran%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dihua%22%2C%22lastName%22%3A%22Yu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leng%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radbod%22%2C%22lastName%22%3A%22Darabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liuqing%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Javid%20J.%22%2C%22lastName%22%3A%22Moslehi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chunru%22%2C%22lastName%22%3A%22Lin%22%7D%5D%2C%22abstractNote%22%3A%22Immune%20checkpoint%20inhibitors%20%28ICIs%29%20have%20been%20increasingly%20used%20in%20combination%20for%20cancer%20treatment%20but%20are%20associated%20with%20myocarditis.%20Here%2C%20we%20report%20that%20tumor-bearing%20mice%20exhibited%20response%20to%20treatment%20with%20combinatorial%20anti-programmed%20cell%20death%201%20and%20anti-cytotoxic%20T%20lymphocyte%20antigen-4%20antibodies%20but%20also%20presented%20with%20cardiovascular%20toxicities%20observed%20clinically%20with%20ICI%20therapy%2C%20including%20myocarditis%20and%20arrhythmia.%20Female%20mice%20were%20preferentially%20affected%20with%20myocarditis%20compared%20to%20male%20mice%2C%20consistent%20with%20a%20previously%20described%20genetic%20model%20of%20ICI%20myocarditis%20and%20emerging%20clinical%20data.%20Mechanistically%2C%20myocardial%20tissue%20from%20ICI-treated%20mice%2C%20the%20genetic%20mouse%20model%2C%20and%20human%20heart%20tissue%20from%20affected%20patients%20with%20ICI%20myocarditis%20all%20exhibited%20down-regulation%20of%20MANF%20%28mesencephalic%20astrocyte-derived%20neurotrophic%20factor%29%20and%20HSPA5%20%28heat%20shock%2070-kDa%20protein%205%29%20in%20the%20heart%3B%20this%20down-regulation%20was%20particularly%20notable%20in%20female%20mice.%20ICI%20myocarditis%20was%20amplified%20by%20heart-specific%20genetic%20deletion%20of%20mouse%20Manf%20and%20was%20attenuated%20by%20administration%20of%20recombinant%20MANF%20protein%2C%20suggesting%20a%20causal%20role.%20Ironically%2C%20both%20MANF%20and%20HSPA5%20were%20transcriptionally%20induced%20by%20liganded%20estrogen%20receptor%20%5Cu03b2%20and%20inhibited%20by%20androgen%20receptor.%20However%2C%20ICI%20treatment%20reduced%20serum%20estradiol%20concentration%20to%20a%20greater%20extent%20in%20female%20compared%20to%20male%20mice.%20Treatment%20with%20an%20estrogen%20receptor%20%5Cu03b2-specific%20agonist%20and%20androgen%20depletion%20therapy%20attenuated%20ICI-associated%20cardiac%20effects.%20Together%2C%20our%20data%20suggest%20that%20ICI%20treatment%20inhibits%20estradiol-dependent%20expression%20of%20MANF%5C%2FHSPA5%20in%20the%20heart%2C%20curtailing%20the%20cardiomyocyte%20response%20to%20immune%20injury.%20This%20endocrine-cardiac-immune%20pathway%20offers%20new%20insights%20into%20the%20mechanisms%20of%20sex%20differences%20in%20cardiac%20disease%20and%20may%20offer%20treatment%20strategies%20for%20ICI%20myocarditis.%22%2C%22date%22%3A%222022-11-02%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1126%5C%2Fscitranslmed.abo1981%22%2C%22ISSN%22%3A%221946-6242%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%224VC6SC4L%22%2C%22QF52JASW%22%5D%2C%22dateModified%22%3A%222023-01-12T19%3A37%3A44Z%22%7D%7D%2C%7B%22key%22%3A%22WZU674H4%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Li%20et%20al.%22%2C%22parsedDate%22%3A%222022-08-03%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLi%2C%20K.%2C%20Segura%2C%20A.%20M.%2C%20Sun%2C%20J.%20et%20al.%20%282022%29.%20Rare%20delayed%20cardiac%20tamponade%20in%20a%20pig%20after%20cardiac%20surgery.%20%26lt%3Bi%26gt%3BVet%20Med%20Sci%26lt%3B%5C%2Fi%26gt%3B.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fvms3.892%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fvms3.892%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Rare%20delayed%20cardiac%20tamponade%20in%20a%20pig%20after%20cardiac%20surgery%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ke%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ana%20Maria%22%2C%22lastName%22%3A%22Segura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junping%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Emerson%20C.%22%2C%22lastName%22%3A%22Perin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdelmotagaly%22%2C%22lastName%22%3A%22Elgalad%22%7D%5D%2C%22abstractNote%22%3A%22OBJECTIVE%3A%20Delayed%20cardiac%20tamponade%2C%20a%20life-threatening%20complication%20of%20pericardial%20effusion%20in%20humans%2C%20has%20rarely%20been%20described%20in%20large%20animal%20models.%20We%20report%20here%20a%20pig%20with%20cardiac%20tamponade%20that%20developed%2029%20days%20after%20cardiac%20surgery.%5CnSTUDY%20DESIGN%3A%20Case%20report.%5CnANIMALS%3A%20One%2045-kg%20domestic%20pig.%5CnMETHODS%3A%20Open-chest%20surgery%20was%20performed%20on%20a%20pig%20to%20induce%20chronic%20heart%20failure.%20At%2015%20days%20after%20surgery%2C%20the%20pig%26%23039%3Bs%20breathing%20appeared%20laboured%3B%20induced%20heart%20failure%20was%20considered%20the%20cause.%20Routine%20heart%20failure%20medications%20were%20administered.%5CnRESULTS%3A%20On%20day%2028%2C%20the%20pig%26%23039%3Bs%20status%20deteriorated.%20On%20day%2029%2C%20echocardiography%20performed%20just%20before%20the%20pig%26%23039%3Bs%20death%20showed%20a%20large%20pericardial%20effusion%2C%20mainly%20in%20the%20lateral%20and%20anterior%20walls%20of%20the%20right%20heart%2C%20with%20several%20fibre%20exudation%20bands.%20The%20right%20heart%20was%20severely%20compressed%20with%20an%20extremely%20small%20right%20ventricle.%20An%20emergency%20sternotomy%20was%20unsuccessful.%20Pathologic%20examination%20showed%20a%20severely%20thickened%2C%20fibrous%20pericardium.%20The%20pericardial%20sac%20was%20distended%20%28up%20to%204.5%5Cu00a0cm%29%20and%20was%20full%20of%20dark%20brown%2C%20soft%2C%20friable%20material.%20Epicardial%20haemorrhage%20with%20a%20fresh%2C%20organised%20thrombus%20was%20noted%20in%20the%20pericardium.%5CnCONCLUSION%3A%20Delayed%20tamponade%20occurring%20at%20least%2015%20days%20after%20open-chest%20surgery%20is%20easy%20to%20misdiagnose%20or%20overlook%20in%20large%20animal%20models%20where%20attention%20is%20often%20focused%20on%20primary%20pathological%20model%20changes.%20To%20decrease%20mortality%20in%20animal%20models%2C%20researchers%20should%20be%20aware%20of%20potential%20complications%20and%20use%20the%20same%20level%20of%20follow-up%20monitoring%20of%20large%20animals%20as%20in%20clinical%20care.%22%2C%22date%22%3A%22Aug%2003%202022%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fvms3.892%22%2C%22ISSN%22%3A%222053-1095%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%228HHBIBI6%22%2C%2242FKW3I4%22%2C%22RB23UBKZ%22%2C%22558WQRIW%22%2C%22CA7YD8T8%22%2C%226CLB47ZH%22%2C%228PULYTSK%22%2C%22VTWWYEIB%22%5D%2C%22dateModified%22%3A%222022-09-02T20%3A14%3A08Z%22%7D%7D%2C%7B%22key%22%3A%22RZHSHNHU%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Chen%20et%20al.%22%2C%22parsedDate%22%3A%222021-10%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BChen%2C%20Q.%2C%20Pollet%2C%20M.%2C%20Mehta%2C%20A.%20et%20al.%20%282021%29.%20Delayed%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20for%20patients%20undergoing%20catheter%20ablation%20of%20ventricular%20tachycardia%20is%20associated%20with%20increased%2090-day%20mortality.%20%26lt%3Bi%26gt%3BJ%20Interv%20Card%20Electrophysiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B62%26lt%3B%5C%2Fi%26gt%3B%2C%2049%26%23x2013%3B56.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-020-00875-y%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-020-00875-y%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Delayed%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20for%20patients%20undergoing%20catheter%20ablation%20of%20ventricular%20tachycardia%20is%20associated%20with%20increased%2090-day%20mortality%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mark%22%2C%22lastName%22%3A%22Pollet%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Adwait%22%2C%22lastName%22%3A%22Mehta%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shuyu%22%2C%22lastName%22%3A%22Wang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Juliette%22%2C%22lastName%22%3A%22Dean%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jennifer%22%2C%22lastName%22%3A%22Parenti%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Francia%22%2C%22lastName%22%3A%22Rojas-Delgado%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leo%22%2C%22lastName%22%3A%22Simpson%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nilesh%22%2C%22lastName%22%3A%22Mathuria%22%7D%5D%2C%22abstractNote%22%3A%22PURPOSE%3A%20Assess%20if%20timing%20of%20removal%20of%20a%20percutaneous%20left%20ventricular%20assist%20device%20%28pLVAD%29%20after%20ventricular%20tachycardia%20%28VT%29%20ablation%20alters%20patient%20outcomes.%5CnMETHODS%3A%20Sixty-nine%20patients%20underwent%20pLVAD%20support.%20Patients%20were%20divided%20into%20early%20%28%26lt%3B%5Cu200924%5Cu00a0h%2C%20n%5Cu00a0%3D%5Cu200943%29%20and%20delayed%20%28%5Cu2265%5Cu200924%5Cu00a0h%2C%20n%5Cu00a0%3D%5Cu200926%29%20removal%20groups%20after%20ablation.%20Factors%20for%20delayed%20pLVAD%20removal%20and%20predictors%20of%2090-day%20mortality%20were%20analyzed.%5CnRESULTS%3A%20The%20delayed%20removal%20group%20had%20lower%20LVEF%20%2827.1%5Cu2009%5Cu00b1%5Cu20099.3%25%20vs.%2020.6%5Cu2009%5Cu00b1%5Cu20095.4%25%2C%20p%5Cu2009%3D%5Cu20090.002%29%2C%20greater%20percentage%20LVEF%20%26lt%3B%5Cu200925%25%20%2858.1%25%20vs.%2084.6%25%2C%20p%5Cu2009%3D%5Cu20090.02%29%2C%20and%20more%20VT%20storm%20%2841.9%25%20vs.%2096.2%25%2C%20p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Ventricular%20fibrillation%20%28VF%29%20was%20induced%20in%209%5C%2F69%20%2813%25%29%2C%20with%20incidence%20higher%20in%20delayed%20removal%20group%20%2827%25%20vs.%205%25%2C%20p%5Cu2009%3D%5Cu20090.002%29.%20VT%20storm%20%28OR%5Cu2009%3D%5Cu200934.72%2C%2095%25%20CI%2C%204.30-280.33%3B%20p%5Cu2009%3D%5Cu20090.001%29%2C%20LVEF%20%26lt%3B%5Cu200925%25%20%28OR%5Cu2009%3D%5Cu20093.95%2C%2095%25%20CI%2C%201.16-13.48%3B%20p%5Cu2009%3D%5Cu20090.03%29%2C%20and%20VF%20induced%20during%20ablation%20%28OR%5Cu2009%3D%5Cu20099.25%2C%2095%25%20CI%2C%201.71-50.0%3B%20p%5Cu2009%3D%5Cu20090.01%29%20were%20associated%20with%20delayed%20pLVAD%20removal%20in%20univariate%20analysis.%20Delayed%20pLVAD%20removal%20had%20a%20significantly%20higher%2090-day%20mortality%20rate%20%282.3%25%20vs%2030.2%25%3B%20p%5Cu2009%26lt%3B%5Cu20090.001%29.%20Univariate%20Cox%20proportional%20hazard%20regression%20analysis%20revealed%20delayed%20pLVAD%20removal%20was%20a%20significant%20predictor%20of%2090-day%20mortality.%5CnCONCLUSIONS%3A%20Prolonged%20pLVAD%20insertion%20%28%5Cu2265%5Cu00a024%5Cu00a0h%29%20after%20VT%20ablation%20was%20associated%20with%20VT%20storm%2C%20LVEF%20%26lt%3B%5Cu200925%25%2C%20and%20VF%20induced%20during%20ablation.%20Delayed%20pLVAD%20removal%20was%20a%20significant%20predictor%20of%2090-day%20mortality%20in%20patients%20undergoing%20VT%20ablation.%22%2C%22date%22%3A%22Oct%202021%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10840-020-00875-y%22%2C%22ISSN%22%3A%221572-8595%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%22AAQ89W3S%22%2C%22CEPAWXUI%22%2C%22B2JSS4XR%22%2C%22R4DG8MRF%22%2C%226CLB47ZH%22%5D%2C%22dateModified%22%3A%222021-10-07T17%3A45%3A54Z%22%7D%7D%2C%7B%22key%22%3A%2228G8M3PG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhang%20et%20al.%22%2C%22parsedDate%22%3A%222020-11%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZhang%2C%20Y.%2C%20Li%2C%20Y.%2C%20Hu%2C%20Q.%20et%20al.%20%282020%29.%20The%20lncRNA%20H19%20alleviates%20muscular%20dystrophy%20by%20stabilizing%20dystrophin.%20%26lt%3Bi%26gt%3BNat%20Cell%20Biol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B22%26lt%3B%5C%2Fi%26gt%3B%2C%201332%26%23x2013%3B1345.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41556-020-00595-5%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1038%5C%2Fs41556-020-00595-5%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22The%20lncRNA%20H19%20alleviates%20muscular%20dystrophy%20by%20stabilizing%20dystrophin%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yaohua%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yajuan%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qingsong%22%2C%22lastName%22%3A%22Hu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yutao%22%2C%22lastName%22%3A%22Xi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhen%22%2C%22lastName%22%3A%22Xing%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zhao%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lisa%22%2C%22lastName%22%3A%22Huang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jianbo%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ke%22%2C%22lastName%22%3A%22Liang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tina%20K.%22%2C%22lastName%22%3A%22Nguyen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sergey%20D.%22%2C%22lastName%22%3A%22Egranov%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chengcao%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Zilong%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20H.%22%2C%22lastName%22%3A%22Hawke%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jin%22%2C%22lastName%22%3A%22Li%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Deqiang%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jean%20J.%22%2C%22lastName%22%3A%22Kim%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ping%22%2C%22lastName%22%3A%22Zhang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abid%22%2C%22lastName%22%3A%22Farida%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mien-Chie%22%2C%22lastName%22%3A%22Hung%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Leng%22%2C%22lastName%22%3A%22Han%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radbod%22%2C%22lastName%22%3A%22Darabi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chunru%22%2C%22lastName%22%3A%22Lin%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Liuqing%22%2C%22lastName%22%3A%22Yang%22%7D%5D%2C%22abstractNote%22%3A%22Dystrophin%20proteomic%20regulation%20in%20muscular%20dystrophies%20%28MDs%29%20remains%20unclear.%20We%20report%20that%20a%20long%20noncoding%20RNA%20%28lncRNA%29%2C%20H19%2C%20associates%20with%20dystrophin%20and%20inhibits%20E3-ligase-dependent%20polyubiquitination%20at%20Lys%5Cu20093584%20%28referred%20to%20as%20Ub-DMD%29%20and%20its%20subsequent%20protein%20degradation.%20In-frame%20deletions%20in%20BMD%20and%20a%20DMD%20non-silent%20mutation%20%28C3340Y%29%20resulted%20in%20defects%20in%20the%20ability%20of%20the%20protein%20to%20interact%20with%20H19%2C%20which%20caused%20elevated%20Ub-DMD%20levels%20and%20dystrophin%20degradation.%20Dmd%20C3333Y%20mice%20exhibited%20progressive%20MD%2C%20elevated%20serum%20creatine%20kinase%2C%20heart%20dilation%2C%20blood%20vessel%20irregularity%20and%20respiratory%20failure%20with%20concurrently%20reduced%20dystrophin%20and%20increased%20Ub-DMD%20status.%20H19%20RNA%20oligonucleotides%20conjugated%20with%20agrin%20%28AGR-H19%29%20and%20nifenazone%20competed%20with%20or%20inhibited%20TRIM63.%20Dmd%20C3333Y%20animals%2C%20induced-pluripotent-stem-cell-derived%20skeletal%20muscle%20cells%20from%20patients%20with%20Becker%20MD%20and%20mdx%20mice%20subjected%20to%20exon%20skipping%20exhibited%20inhibited%20dystrophin%20degradation%2C%20preserved%20skeletal%20and%20cardiac%20muscle%20histology%2C%20and%20improved%20strength%20and%20heart%20function%20following%20AGR-H19%20or%20nifenazone%20treatment.%20Our%20study%20paves%20the%20way%20for%20meaningful%20targeted%20therapeutics%20for%20Becker%20MD%20and%20for%20certain%20patients%20with%20Duchenne%20MD.%22%2C%22date%22%3A%22Nov%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1038%5C%2Fs41556-020-00595-5%22%2C%22ISSN%22%3A%221476-4679%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%224VC6SC4L%22%5D%2C%22dateModified%22%3A%222020-12-07T18%3A38%3A24Z%22%7D%7D%2C%7B%22key%22%3A%22U98WXEYF%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Ma%20et%20al.%22%2C%22parsedDate%22%3A%222020-08-21%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BMa%2C%20Y.%2C%20%26lt%3Bstrong%26gt%3BCheng%26lt%3B%5C%2Fstrong%26gt%3B%2C%20N.%2C%20Sun%2C%20J.%20et%20al.%20%282020%29.%20Atherogenic%20L5%20LDL%20induces%20cardiomyocyte%20apoptosis%20and%20inhibits%20KATP%20channels%20through%20CaMKII%20activation.%20%26lt%3Bi%26gt%3BLipids%20Health%20Dis%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B19%26lt%3B%5C%2Fi%26gt%3B%2C%20189.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12944-020-01368-7%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1186%5C%2Fs12944-020-01368-7%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Atherogenic%20L5%20LDL%20induces%20cardiomyocyte%20apoptosis%20and%20inhibits%20KATP%20channels%20through%20CaMKII%20activation%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanzhuo%22%2C%22lastName%22%3A%22Ma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nancy%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Junping%22%2C%22lastName%22%3A%22Sun%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jonathan%20Xuhai%22%2C%22lastName%22%3A%22Lu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Shahrzad%22%2C%22lastName%22%3A%22Abbasi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Geru%22%2C%22lastName%22%3A%22Wu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22An-Sheng%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tatsuya%22%2C%22lastName%22%3A%22Sawamura%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Chu-Huang%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yutao%22%2C%22lastName%22%3A%22Xi%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Cardiac%20Ca2%2B%5C%2Fcalmodulin-dependent%20protein%20kinase%20II%20%28CaMKII%29%20activation%20plays%20a%20critical%20role%20in%20cardiomyocyte%20%28CM%29%20apoptosis%20and%20arrhythmia.%20Functional%20ATP-sensitive%20potassium%20%28KATP%29%20channels%20are%20essential%20for%20cardiac%20protection%20during%20ischemia.%20In%20cultured%20CMs%2C%20L5%20low-density%20lipoprotein%20%28LDL%29%20induces%20apoptosis%20and%20QTc%20prolongation.%20L5%20is%20a%20highly%20electronegative%20and%20atherogenic%20aberrant%20form%20of%20LDL%2C%20and%20its%20levels%20are%20significantly%20higher%20in%20patients%20with%20cardiovascular-related%20diseases.%20Here%2C%20the%20role%20of%20L5%20in%20cardiac%20injury%20was%20studied%20by%20evaluating%20the%20effects%20of%20L5%20on%20CaMKII%20activity%20and%20KATP%20channel%20physiology%20in%20CMs.%5CnMETHODS%3A%20Cultured%20neonatal%20rat%20CMs%20%28NRCMs%29%20were%20treated%20with%20a%20moderate%20concentration%20%28ie%2C%207.5%5Cu2009%5Cu03bcg%5C%2FmL%29%20of%20L5%20or%20L1%20%28the%20least%20electronegative%20LDL%20subfraction%29.%20NRCMs%20were%20examined%20for%20apoptosis%20and%20viability%2C%20CaMKII%20activity%2C%20and%20the%20expression%20of%20phosphorylated%20CaMKII%5Cu03b4%20and%20NOX2%5C%2Fgp91phox.%20The%20function%20of%20KATP%20and%20action%20potentials%20%28APs%29%20was%20analyzed%20by%20using%20the%20patch-clamp%20technique.%5CnRESULTS%3A%20In%20NRCMs%2C%20L5%20but%20not%20L1%20significantly%20induced%20cell%20apoptosis%20and%20reduced%20cell%20viability.%20Furthermore%2C%20L5%20decreased%20Kir6.2%20expression%20by%20more%20than%2050%25.%20Patch-clamp%20analysis%20showed%20that%20L5%20reduced%20the%20KATP%20current%20%28IKATP%29%20density%20induced%20by%20pinacidil%2C%20a%20KATP%20opener.%20The%20partial%20recovery%20of%20the%20inward%20potassium%20current%20during%20pinacidil%20washout%20was%20susceptible%20to%20subsequent%20inhibition%20by%20the%20IKATP%20blocker%20glibenclamide.%20Suppression%20of%20IKATP%20by%20L5%20significantly%20prolonged%20the%20AP%20duration.%20L5%20also%20significantly%20increased%20the%20activity%20of%20CaMKII%2C%20the%20phosphorylation%20of%20CaMKII%5Cu03b4%2C%20and%20the%20expression%20of%20NOX2%5C%2Fgp91phox.%20L5-induced%20apoptosis%20was%20prevented%20by%20the%20addition%20of%20the%20CaMKII%20inhibitor%20KN93%20and%20the%20reactive%20oxygen%20species%20scavenger%20Mn%20%28III%29TBAP.%5CnCONCLUSIONS%3A%20L5%20but%20not%20L1%20induces%20CM%20damage%20through%20the%20activation%20of%20the%20CaMKII%20pathway%20and%20increases%20arrhythmogenicity%20in%20CMs%20by%20modulating%20the%20AP%20duration.%20These%20results%20help%20to%20explain%20the%20harmful%20effects%20of%20L5%20in%20cardiovascular-related%20disease.%22%2C%22date%22%3A%22Aug%2021%2C%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1186%5C%2Fs12944-020-01368-7%22%2C%22ISSN%22%3A%221476-511X%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%22IVWSNHMB%22%2C%228EPJLFD3%22%2C%22JH9V95Q8%22%2C%22RB23UBKZ%22%5D%2C%22dateModified%22%3A%222020-09-15T17%3A41%3A07Z%22%7D%7D%2C%7B%22key%22%3A%22VTZ9Y56T%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parikh%20et%20al.%22%2C%22parsedDate%22%3A%222020-04%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BParikh%2C%20V.%2C%20Rasekh%2C%20A.%2C%20Mohanty%2C%20S.%20et%20al.%20%282020%29.%20Exclusion%20of%20electrical%20and%20mechanical%20function%20of%20the%20left%20atrial%20appendage%20in%20patients%20with%20persistent%20atrial%20fibrillation%3A%20differences%20in%20efficacy%20and%20safety%20between%20endocardial%20ablation%20vs%20epicardial%20LARIAT%20ligation%20%28the%20EXCLUDE%20LAA%20study%29.%20%26lt%3Bi%26gt%3BJ%20Interv%20Card%20Electrophysiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B57%26lt%3B%5C%2Fi%26gt%3B%2C%20409%26%23x2013%3B416.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-019-00657-1%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1007%5C%2Fs10840-019-00657-1%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Exclusion%20of%20electrical%20and%20mechanical%20function%20of%20the%20left%20atrial%20appendage%20in%20patients%20with%20persistent%20atrial%20fibrillation%3A%20differences%20in%20efficacy%20and%20safety%20between%20endocardial%20ablation%20vs%20epicardial%20LARIAT%20ligation%20%28the%20EXCLUDE%20LAA%20study%29%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valay%22%2C%22lastName%22%3A%22Parikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdi%22%2C%22lastName%22%3A%22Rasekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sanghamitra%22%2C%22lastName%22%3A%22Mohanty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Bharath%22%2C%22lastName%22%3A%22Yarlagadda%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Donita%22%2C%22lastName%22%3A%22Atkins%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sudha%22%2C%22lastName%22%3A%22Bommana%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohit%22%2C%22lastName%22%3A%22Turagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Courtney%22%2C%22lastName%22%3A%22Jeffery%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Heidi%22%2C%22lastName%22%3A%22Carroll%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Cheri%22%2C%22lastName%22%3A%22Nydegger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Misty%22%2C%22lastName%22%3A%22Jaeger%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Tawseef%22%2C%22lastName%22%3A%22Dar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rakesh%22%2C%22lastName%22%3A%22Gopinnathanair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Luigi%22%2C%22lastName%22%3A%22Dibiase%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Randal%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rodney%22%2C%22lastName%22%3A%22Horton%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Natale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanunjaya%22%2C%22lastName%22%3A%22Lakkireddy%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Electrical%20isolation%20of%20the%20left%20atrial%20appendage%20%28LAA%29%20may%20provide%20incremental%20benefits%20for%20arrhythmia%20management%20in%20patients%20undergoing%20radiofrequency%20ablation%20%28RFA%29%20for%20persistent%20atrial%20fibrillation%20%28AF%29.%5CnOBJECTIVE%3A%20The%20aim%20of%20this%20study%20was%20to%20compare%20efficacy%20and%20safety%20of%20endocardial%20ablation%20and%20LAA%20exclusion%20with%20LARIAT%20device%20for%20electrical%20and%20mechanical%20exclusion%20of%20LAA.%5CnMETHODS%3A%20We%20compared%20patients%20who%20underwent%20endocardial%20LAA%20isolation%20during%20index%20RFA%20for%20persistent%20AF%20and%20underwent%20a%20repeat%20RFA%20to%20patients%20who%20underwent%20LAA%20exclusion%20with%20LARIAT%20device%20followed%20by%20RFA%20for%20AF%20in%20this%20multicenter%20registry.%20Efficacy%20of%20electrical%20and%20mechanical%20isolation%20of%20LAA%20was%20assessed.%5CnRESULTS%3A%20We%20included%20182%20patients%20of%20which%2091%20patients%20underwent%20endocardial%20LAA%20isolation%20during%20RFA%20for%20AF%2C%20and%2091%20patients%20underwent%20LAA%20exclusion%20with%20LARIAT%20device%20followed%20by%20RFA%20for%20AF.%20Baseline%20characteristics%20were%20similar%20except%20for%20higher%20CHA2DS2-VASc%20score%2C%20coronary%20artery%20disease%2C%20and%20prior%20stroke%20rate%20in%20LARIAT%20arm.%20Persistence%20of%20electrical%20isolation%20%28measured%20at%20beginning%20of%20second%20procedure%29%20after%20LARIAT%20procedure%20was%20higher%20than%20one-time%20AF-RFA%20%2896.7%25%20vs%2052.8%25%2C%20p%20%26lt%3B%200.01%29.%20Acute%20pulmonary%20vein%20isolation%20rates%20were%20similar%20in%20both%20arms.%20AF%20recurrence%20rate%20after%20second%20isolation%20attempts%20at%201%20year%20was%20similar%20in%20both%20arms.%20No%20difference%20in%20major%20complications%20was%20noted%20between%20both%20arms.%5CnCONCLUSIONS%3A%20LAA%20exclusion%20with%20LARIAT%20device%20appears%20to%20be%20more%20efficacious%20as%20compared%20to%20one-time%20endocardial%20ablation%2C%20but%20not%20compared%20to%20repeat%20isolation%2C%20in%20achieving%20complete%20electrical%20isolation%20of%20LAA%20for%20persistent%20AF.%22%2C%22date%22%3A%22Apr%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1007%5C%2Fs10840-019-00657-1%22%2C%22ISSN%22%3A%221572-8595%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%22DYX9DYCW%22%5D%2C%22dateModified%22%3A%222022-02-14T21%3A25%3A32Z%22%7D%7D%2C%7B%22key%22%3A%2274BI8NPG%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Long%20et%20al.%22%2C%22parsedDate%22%3A%222020-03%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BLong%2C%20S.%2C%20Xi%2C%20Y.%2C%20Gao%2C%20L.%20et%20al.%20%282020%29.%20Safety%20and%20efficacy%20of%20catheter%20ablation%20in%20atrial%20fibrillation%20patients%20with%20left%20ventricular%20dysfunction.%20%26lt%3Bi%26gt%3BClin%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B43%26lt%3B%5C%2Fi%26gt%3B%2C%20305%26%23x2013%3B314.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fclc.23314%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1002%5C%2Fclc.23314%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Safety%20and%20efficacy%20of%20catheter%20ablation%20in%20atrial%20fibrillation%20patients%20with%20left%20ventricular%20dysfunction%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Songbing%22%2C%22lastName%22%3A%22Long%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yutao%22%2C%22lastName%22%3A%22Xi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lianjun%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanzong%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunlong%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaomeng%22%2C%22lastName%22%3A%22Yin%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Catheter%20ablation%20%28CA%29%20for%20atrial%20fibrillation%20%28AF%29%20in%20heart%20failure%20%28HF%29%20patients%20reduced%20the%20mortality%20but%20may%20increase%20complications%20and%20raise%20the%20safety%20concern.%5CnHYPOTHESIS%3A%20CA%20for%20AF%20in%20HF%20patients%20may%20not%20increase%20the%20complications%20vs%20medical%20treatment%2C%20and%20it%20may%20reduce%20hospitalizations%20and%20mortality%20and%20improve%20heart%20function.%5CnMETHODS%3A%20Three%20groups%20of%20AF%20patients%20were%20included%20in%20the%20study%3A%20120%20congestive%20HF%20for%20their%20first%20CA%20%28AFHF-CA%29%2C%20150%20congestive%20HF%20who%20were%20undergoing%20medical%20therapy%20%28AFHF-Med%29%2C%20and%20150%20patients%20with%20normal%20left%20ventricular%20%28LV%29%20ejection%20fraction%20%28LVEF%29%20%28AF-CA%29.%5CnRESULTS%3A%20After%2030%5Cu2009%5Cu00b1%5Cu20096%20months%20of%20follow%20up%2C%2045.8%25%20of%20patients%20in%20the%20AFHF-CA%20and%2061.3%25%20of%20patients%20in%20the%20AF-CA%20groups%20maintained%20sinus%20rhythm%20%28SR%29%20in%20comparison%20with%202.7%25%20in%20AFHF-Med%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29.%20Hospitalization%20for%20HF%20was%20significantly%20lower%20in%20AFHF-CA%20than%20in%20AFHF-Med%20groups%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29.%20Death%20occurred%20in%207.5%25%20of%20patients%20in%20the%20AFHF-CA%20group%2C%20which%20was%20lower%20than%2018%25%20in%20the%20AFHF-Med%20group%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29.%20Significant%20improvements%20in%20heart%20function%20were%20shown%20in%20the%20AFHF-CA%20group%20compared%20to%20the%20AFHF-Med%20group%2C%20including%20LVEF%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29%2C%20LV%20end-diastolic%20diameter%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29%2C%20and%20New%20York%20Heart%20Association%20classification%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29%2C%20as%20well%20as%20the%20left%20atrial%20diameter%20%28P%5Cu2009%26lt%3B%5Cu2009.01%29.%20AFHF-CA%20patients%20required%20additional%20ablation%20more%20often%20%28P%5Cu2009%26lt%3B%5Cu2009.05%29.%20CA%20had%20a%20better%20prognosis%20in%20paroxysmal%20AF%20and%20tachycardia-related%20diseases.%5CnCONCLUSION%3A%20CA%20for%20AF%20reduced%20hospitalizations%20and%20mortality%20and%20improved%20heart%20function%2C%20vs%20medical%20treatment%2C%20and%20was%20as%20safe%20as%20CA%20in%20those%20with%20normal%20heart%20function.%22%2C%22date%22%3A%22Mar%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1002%5C%2Fclc.23314%22%2C%22ISSN%22%3A%221932-8737%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%224VC6SC4L%22%2C%226CLB47ZH%22%5D%2C%22dateModified%22%3A%222020-10-07T22%3A47%3A02Z%22%7D%7D%2C%7B%22key%22%3A%22NU5D2ZMS%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Zhao%20et%20al.%22%2C%22parsedDate%22%3A%222020-02%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BZhao%2C%20Z.%2C%20Liu%2C%20X.%2C%20Gao%2C%20L.%20et%20al.%20%282020%29.%20Benefit%20of%20contact%20force-guided%20catheter%20ablation%20for%20treating%20premature%20ventricular%20contractions.%20%26lt%3Bi%26gt%3BTex%20Heart%20Inst%20J%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B47%26lt%3B%5C%2Fi%26gt%3B%2C%203%26%23x2013%3B9.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-17-6441%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.14503%5C%2FTHIJ-17-6441%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Benefit%20of%20contact%20force-guided%20catheter%20ablation%20for%20treating%20premature%20ventricular%20contractions%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Ziming%22%2C%22lastName%22%3A%22Zhao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaowei%22%2C%22lastName%22%3A%22Liu%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lianjun%22%2C%22lastName%22%3A%22Gao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yutao%22%2C%22lastName%22%3A%22Xi%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Qi%22%2C%22lastName%22%3A%22Chen%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dong%22%2C%22lastName%22%3A%22Chang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xianjie%22%2C%22lastName%22%3A%22Xiao%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yanzong%22%2C%22lastName%22%3A%22Yang%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Yunlong%22%2C%22lastName%22%3A%22Xia%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Xiaomeng%22%2C%22lastName%22%3A%22Yin%22%7D%5D%2C%22abstractNote%22%3A%22We%20evaluated%20whether%20an%20irrigated%20contact%20force-sensing%20catheter%20would%20improve%20the%20safety%20and%20effectiveness%20of%20radiofrequency%20ablation%20of%20premature%20ventricular%20contractions%20originating%20from%20the%20right%20ventricular%20outflow%20tract.%20We%20retrospectively%20reviewed%20the%20charts%20of%20patients%20with%20symptomatic%20premature%20ventricular%20contractions%20who%20underwent%20ablation%20with%20a%20contact%20force-sensing%20catheter%20%2856%20patients%2C%20SmartTouch%29%20or%20conventional%20catheter%20%2859%20patients%2C%20ThermoCool%29%20at%20our%20hospital%20from%20August%202013%20through%20December%202015.%20During%20a%20mean%20follow-up%20of%2016%20%5Cu00b1%205%20months%2C%203%20patients%20in%20the%20conventional%20group%20had%20recurrences%2C%20compared%20with%20none%20in%20the%20contact%20force%20group.%20Complications%20occurred%20only%20in%20the%20conventional%20group%20%28one%20steam%20pop%3B%202%20ablations%20suspended%20because%20of%20significantly%20increasing%20impedance%29.%20In%20the%20contact%20force%20group%2C%20the%20median%20contact%20force%20during%20ablation%20was%2010%20g%20%28interquartile%20range%2C%207-14%20g%29.%20Times%20for%20overall%20procedure%20%2836.9%20%5Cu00b1%205%20min%29%2C%20fluoroscopy%20%2886.3%20%5Cu00b1%2022.7%20s%29%2C%20and%20ablation%20%2860.3%20%5Cu00b1%2021.4%20s%29%20were%20significantly%20shorter%20in%20the%20contact%20force%20group%20than%20in%20the%20conventional%20group%20%2846.2%20%5Cu00b1%206.2%20min%2C%20107.7%20%5Cu00b1%2030%20s%2C%20and%2088.7%20%5Cu00b1%2032.3%20s%2C%20respectively%3B%20P%20%26lt%3B0.001%29.%20In%20the%20contact%20force%20group%2C%20cases%20with%20a%20force-time%20integral%20%26lt%3B560%20gram-seconds%20%28g-s%29%20had%20significantly%20longer%20procedure%20and%20fluoroscopy%20times%20%28both%20P%20%26lt%3B0.001%29%20than%20did%20those%20with%20a%20force-time%20integral%20%5Cu2265560%20g-s.%20These%20findings%20suggest%20that%20ablation%20of%20premature%20ventricular%20contractions%20originating%20from%20the%20right%20ventricular%20outflow%20tract%20with%20an%20irrigated%20contact%20force-sensing%20catheter%20instead%20of%20a%20conventional%20catheter%20shortens%20overall%20procedure%2C%20fluoroscopy%2C%20and%20ablation%20times%20without%20increasing%20risk%20of%20recurrence%20or%20complications.%22%2C%22date%22%3A%22Feb%202020%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.14503%5C%2FTHIJ-17-6441%22%2C%22ISSN%22%3A%221526-6702%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%226CLB47ZH%22%5D%2C%22dateModified%22%3A%222020-04-20T19%3A39%3A18Z%22%7D%7D%2C%7B%22key%22%3A%22U3FU6K7I%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Parikh%20et%20al.%22%2C%22parsedDate%22%3A%222019-12%22%2C%22numChildren%22%3A2%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BParikh%2C%20V.%2C%20Bartus%2C%20K.%2C%20Litwinowicz%2C%20R.%20et%20al.%20%282019%29.%20Long-term%20clinical%20outcomes%20from%20real-world%20experience%20of%20left%20atrial%20appendage%20exclusion%20with%20LARIAT%20device.%20%26lt%3Bi%26gt%3BJ%20Cardiovasc%20Electrophysiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B30%26lt%3B%5C%2Fi%26gt%3B%2C%202849%26%23x2013%3B2857.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjce.14229%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1111%5C%2Fjce.14229%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Long-term%20clinical%20outcomes%20from%20real-world%20experience%20of%20left%20atrial%20appendage%20exclusion%20with%20LARIAT%20device%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Valay%22%2C%22lastName%22%3A%22Parikh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Krzysztof%22%2C%22lastName%22%3A%22Bartus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Radoslaw%22%2C%22lastName%22%3A%22Litwinowicz%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohit%20K.%22%2C%22lastName%22%3A%22Turagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jerzy%22%2C%22lastName%22%3A%22Sadowski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Boguslaw%22%2C%22lastName%22%3A%22Kapelak%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Magdalena%22%2C%22lastName%22%3A%22Bartus%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jakub%22%2C%22lastName%22%3A%22Podolec%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Maciej%22%2C%22lastName%22%3A%22Brzezinski%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dan%22%2C%22lastName%22%3A%22Musat%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Abdi%22%2C%22lastName%22%3A%22Rasekh%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Suneet%22%2C%22lastName%22%3A%22Mittal%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Nitish%22%2C%22lastName%22%3A%22Badhwar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Randall%22%2C%22lastName%22%3A%22Lee%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanunjaya%22%2C%22lastName%22%3A%22Lakkireddy%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Left%20atrial%20appendage%20closure%20%28LAAC%29%20with%20LARIAT%20has%20emerged%20as%20one%20of%20the%20alternatives%20to%20oral%20anticoagulation%20%28OAC%29%20in%20patients%20with%20nonvalvular%20atrial%20fibrillation%20%28AF%29.%20Our%20aim%20was%20to%20study%20long-term%20outcomes%20in%20patients%20undergoing%20LARIAT%20procedure.%5CnMETHODS%3A%20We%20analyzed%20patients%20screened%20for%20LARIAT%20device%20in%20four%20centers%20between%20December%202009%20and%20June%202012.%20Out%20of%20these%2C%20patients%20who%20didn%26%23039%3Bt%20undergo%20LAAC%20with%20the%20LARIAT%20device%20due%20to%20unfavorable%20LAA%20morphology%20and%20other%20preprocedural%20contraindications%20were%20included%20in%20control%20group.%20We%20analyzed%20thromboembolism%2C%20bleeding%20events%2C%20and%20mortality%20between%20LAA%20and%20control%20group.%5CnRESULTS%3A%20About%20153%20patients%20were%20screened.%20Out%20of%20these%2C%20108%20%2870.6%25%29%20patients%20underwent%20LARIAT%20placement%20%28LAA%20arm%29%20and%2045%20%2829.4%25%29%20excluded%20patients%20were%20included%20in%20control%20arm.%20There%20were%20no%20differences%20in%20CHADS2%20and%20CHA2%20DS2%20-VASc%20score.%20Mean%20HAS-BLED%20score%20was%20significantly%20higher%20in%20the%20LARIAT%20group%20%283.5%5Cu2009%5Cu00b1%5Cu20091.06%20vs%203.09%5Cu2009%5Cu00b1%5Cu20091.22%2C%20P%5Cu2009%3D%5Cu2009.04%29.%20Mean%20follow-up%20time%20%28in%20years%29%20was%206.56%5Cu2009%5Cu00b1%5Cu20090.84%20in%20LAA%20and%206.5%5Cu2009%5Cu00b1%5Cu20091.26%20in%20control%20arm.%20During%20follow-up%20period%2C%20the%20LARIAT%20group%20was%20associated%20with%20significantly%20less%20thromboembolic%20events%20%281.9%25%20vs%2024%25%2C%20P%5Cu2009%26lt%3B%5Cu2009.001%29%2C%20bleeding%20events%20%289.2%25%20vs%2024.4%25%2C%20P%5Cu2009%3D%5Cu2009.03%29%2C%20and%20mortality%20%285.6%25%20vs%2020%25%2C%20P%5Cu2009%3D%5Cu2009.01%29%20as%20compared%20with%20the%20control%20group.%5CnCONCLUSIONS%3A%20Long-term%20data%20from%20routine%20clinical%20practice%20from%20our%20study%20suggests%20that%20LAA%20exclusion%20with%20LARIAT%20device%20is%20an%20effective%20treatment%20in%20management%20of%20nonvalvular%20AF%20patients%20with%20high%20risk%20of%20stroke%2C%20bleeding%2C%20and%20mortality.%20Further%20randomized%20trials%2C%20such%20as%20aMAZE%2C%20will%20provide%20more%20insight%20in%20this%20expanding%20field.%22%2C%22date%22%3A%22Dec%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1111%5C%2Fjce.14229%22%2C%22ISSN%22%3A%221540-8167%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%2C%22DYX9DYCW%22%5D%2C%22dateModified%22%3A%222022-02-14T21%3A25%3A28Z%22%7D%7D%2C%7B%22key%22%3A%22LAK3M93M%22%2C%22library%22%3A%7B%22id%22%3A4862227%7D%2C%22meta%22%3A%7B%22creatorSummary%22%3A%22Sharma%20et%20al.%22%2C%22parsedDate%22%3A%222019-11-05%22%2C%22numChildren%22%3A1%7D%2C%22bib%22%3A%22%26lt%3Bdiv%20class%3D%26quot%3Bcsl-bib-body%26quot%3B%20style%3D%26quot%3Bline-height%3A%201.35%3B%20padding-left%3A%201em%3B%20text-indent%3A-1em%3B%26quot%3B%26gt%3B%5Cn%20%20%26lt%3Bdiv%20class%3D%26quot%3Bcsl-entry%26quot%3B%26gt%3BSharma%2C%20S.%20P.%2C%20Turagam%2C%20M.%20K.%2C%20Gopinathannair%2C%20R.%20et%20al.%20%282019%29.%20Direct%20current%20cardioversion%20of%20atrial%26%23xA0%3Bfibrillation%20in%20patients%20with%20left%26%23xA0%3Batrial%20appendage%20occlusion%20devices.%20%26lt%3Bi%26gt%3BJ%20Am%20Coll%20Cardiol%26lt%3B%5C%2Fi%26gt%3B%20%26lt%3Bi%26gt%3B74%26lt%3B%5C%2Fi%26gt%3B%2C%202267%26%23x2013%3B2274.%20%26lt%3Ba%20class%3D%26%23039%3Bzp-DOIURL%26%23039%3B%20href%3D%26%23039%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2019.08.1045%26%23039%3B%26gt%3Bhttps%3A%5C%2F%5C%2Fdoi.org%5C%2F10.1016%5C%2Fj.jacc.2019.08.1045%26lt%3B%5C%2Fa%26gt%3B.%26lt%3B%5C%2Fdiv%26gt%3B%5Cn%26lt%3B%5C%2Fdiv%26gt%3B%22%2C%22data%22%3A%7B%22itemType%22%3A%22journalArticle%22%2C%22title%22%3A%22Direct%20current%20cardioversion%20of%20atrial%5Cu00a0fibrillation%20in%20patients%20with%20left%5Cu00a0atrial%20appendage%20occlusion%20devices%22%2C%22creators%22%3A%5B%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sharan%20Prakash%22%2C%22lastName%22%3A%22Sharma%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Mohit%20K.%22%2C%22lastName%22%3A%22Turagam%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Rakesh%22%2C%22lastName%22%3A%22Gopinathannair%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Vivek%22%2C%22lastName%22%3A%22Reddy%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Saibal%22%2C%22lastName%22%3A%22Kar%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Sangamitra%22%2C%22lastName%22%3A%22Mohanty%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Jie%22%2C%22lastName%22%3A%22Cheng%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22David%20R.%22%2C%22lastName%22%3A%22Holmes%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Lars%22%2C%22lastName%22%3A%22Sondergaard%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Andrea%22%2C%22lastName%22%3A%22Natale%22%7D%2C%7B%22creatorType%22%3A%22author%22%2C%22firstName%22%3A%22Dhanunjaya%22%2C%22lastName%22%3A%22Lakkireddy%22%7D%5D%2C%22abstractNote%22%3A%22BACKGROUND%3A%20Direct%20current%20cardioversion%20%28DCCV%29%20is%20a%20common%20rhythm%20control%20strategy%20in%20patients%20with%20symptomatic%20atrial%20fibrillation%20or%20flutter.%20There%20is%20no%20long-term%20data%20regarding%20the%20safety%20of%20DCCV%20in%20patients%20with%20endocardial%20left%20atrial%20appendage%20occlusion%20%28LAAO%29%20devices.%5CnOBJECTIVES%3A%20The%20purpose%20of%20this%20study%20was%20to%20assess%20the%20feasibility%20and%20safety%20of%20DCCV%20in%20patients%20with%20an%20LAAO%5Cu00a0device.%5CnMETHODS%3A%20This%20multicenter%20retrospective%20study%20included%20148%20patients%20with%20an%20LAAO%20device%20who%20underwent%20DCCV%20for%20symptomatic%20atrial%20fibrillation%20or%20atrial%20flutter.%5CnRESULTS%3A%20The%20average%20age%20of%20the%20included%20patients%20was%2072%20%5Cu00b1%207%20years%20and%2059%25%20were%20men.%20All%20patients%20%28100%25%29%20had%20a%20transesophageal%20echocardiogram%20prior%20to%20DCCV.%20Device-related%20thrombus%20was%20seen%20in%202.7%25.%20They%20were%20all%20successfully%20treated%20with%20oral%20anticoagulation%20%28OAC%29%20and%20were%20able%20to%20undergo%20DCCV%20after%206%20to%208%5Cu00a0weeks.%20DCCV%20restored%20sinus%20rhythm%20in%20all%20patients.%20None%20of%20the%20patients%20had%20DCCV-related%20thromboembolic%20complications.%20A%20total%20of%2022%25%20of%20patients%20were%20newly%20started%20on%20OAC%20after%20DCCV.%20There%20was%20no%20difference%20in%20DCCV-related%20complications%20between%20patients%20treated%20with%20or%20without%20OAC%20post-DCCV.%20Patients%20receiving%20OAC%20post-DCCV%20were%20found%20to%20undergo%20cardioversion%20at%20an%20earlier%20time%20after%20implantation%20%283.6%5Cu00a0months%20%5Binterquartile%20range%20%28IQR%29%3A%200.7%20to%208.6%5Cu00a0months%5D%20vs.%208.6%5Cu00a0months%20%5BIQR%3A%202.5%20to%2013.3%5Cu00a0months%5D%3B%20p%5Cu00a0%3D%5Cu00a00.003%29.%20Three%20transient%20ischemic%20attacks%2C%20unrelated%20to%20DCCV%2C%20were%20found%20during%20follow-up.%20During%20a%20median%20follow-up%20of%2012.8%5Cu00a0months%20%28IQR%3A%2011.8%20to%2014.2%5Cu00a0months%29%2C%20no%20device%20or%20left%20atrial%20thrombosis%2C%20device%20dislodgement%2C%20or%20a%20new%20device%20leak%20were%20observed.%20One%20patient%20died%20during%20follow-up%20due%20to%20noncardiac%20cause.%5CnCONCLUSIONS%3A%20DCCV%20is%20feasible%20in%20high-risk%20AF%20patients%20with%20an%20LAAO%20device%20without%20the%20need%20for%20oral%20anticoagulation%20if%20pre-procedural%20transesophageal%20echocardiography%20shows%20good%20device%20position%2C%20absence%20of%20device-related%20thrombus%2C%20and%20peridevice%20leak%20of%5Cu00a0%5Cu22645%5Cu00a0mm.%20The%20preliminary%20results%20are%20encouraging%2C%20but%20further%20large%20studies%20are%20warranted%20to%20establish%20safety.%22%2C%22date%22%3A%22Nov%2005%2C%202019%22%2C%22language%22%3A%22eng%22%2C%22DOI%22%3A%2210.1016%5C%2Fj.jacc.2019.08.1045%22%2C%22ISSN%22%3A%221558-3597%22%2C%22url%22%3A%22%22%2C%22collections%22%3A%5B%228EPJLFD3%22%5D%2C%22dateModified%22%3A%222019-11-07T20%3A47%3A25Z%22%7D%7D%5D%7D
Zhang, Y., Sun, C., Li, Y. et al. (2022). Hormonal therapies up-regulate MANF and overcome female susceptibility to immune checkpoint inhibitor myocarditis. Sci Transl Med 14, eabo1981. https://doi.org/10.1126/scitranslmed.abo1981.
Li, K., Segura, A. M., Sun, J. et al. (2022). Rare delayed cardiac tamponade in a pig after cardiac surgery. Vet Med Sci. https://doi.org/10.1002/vms3.892.
Chen, Q., Pollet, M., Mehta, A. et al. (2021). Delayed removal of a percutaneous left ventricular assist device for patients undergoing catheter ablation of ventricular tachycardia is associated with increased 90-day mortality. J Interv Card Electrophysiol 62, 49–56. https://doi.org/10.1007/s10840-020-00875-y.
Zhang, Y., Li, Y., Hu, Q. et al. (2020). The lncRNA H19 alleviates muscular dystrophy by stabilizing dystrophin. Nat Cell Biol 22, 1332–1345. https://doi.org/10.1038/s41556-020-00595-5.
Ma, Y., Cheng, N., Sun, J. et al. (2020). Atherogenic L5 LDL induces cardiomyocyte apoptosis and inhibits KATP channels through CaMKII activation. Lipids Health Dis 19, 189. https://doi.org/10.1186/s12944-020-01368-7.
Parikh, V., Rasekh, A., Mohanty, S. et al. (2020). Exclusion of electrical and mechanical function of the left atrial appendage in patients with persistent atrial fibrillation: differences in efficacy and safety between endocardial ablation vs epicardial LARIAT ligation (the EXCLUDE LAA study). J Interv Card Electrophysiol 57, 409–416. https://doi.org/10.1007/s10840-019-00657-1.
Long, S., Xi, Y., Gao, L. et al. (2020). Safety and efficacy of catheter ablation in atrial fibrillation patients with left ventricular dysfunction. Clin Cardiol 43, 305–314. https://doi.org/10.1002/clc.23314.
Zhao, Z., Liu, X., Gao, L. et al. (2020). Benefit of contact force-guided catheter ablation for treating premature ventricular contractions. Tex Heart Inst J 47, 3–9. https://doi.org/10.14503/THIJ-17-6441.
Parikh, V., Bartus, K., Litwinowicz, R. et al. (2019). Long-term clinical outcomes from real-world experience of left atrial appendage exclusion with LARIAT device. J Cardiovasc Electrophysiol 30, 2849–2857. https://doi.org/10.1111/jce.14229.
Sharma, S. P., Turagam, M. K., Gopinathannair, R. et al. (2019). Direct current cardioversion of atrial fibrillation in patients with left atrial appendage occlusion devices. J Am Coll Cardiol 74, 2267–2274. https://doi.org/10.1016/j.jacc.2019.08.1045.

The Texas Heart Institute® at Baylor College of Medicine 2025

Privacy Policy & Terms of Use

Bringing the future of cardiovascular health to life.®